X

INDICATIONS

TAZVERIK is indicated for the treatment of: Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Adult patients with relapsed or refractory…Read more

TAZVERIK is indicated for the treatment of: Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. Adult patients with relapsed or refractory lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Read less

For U.S. Healthcare Professionals Only

header mobile logo

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

This website is for U.S. audiences only

WELCOME.   
PLEASE   
SELECT AN   
OPTION TO   
GET STARTED.

WELCOME. PLEASE SELECT AN OPTION TO GET STARTED.

I am a:
Interested in:

Actor portrayal

TAZVERIK is indicated for the treatment of:

  • Adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies.​
  • Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

ncn logo

Tazemetostat (TAZVERIK®) is included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for 
B-Cell Lymphomas with an NCCN Category 2A recommendation as an option for appropriate patients with R/R FL.2

    View the TAZVERIK safety data

    Learn more about how safety and tolerability were evaluated in the clinical trial.

    SAFETY & TOLERABILITY

    Patient video

    Watch Keith’s video and see his experience of living with R/R FL.

    Watch now

    Learn about oral dosing & administration

    Learn about oral  
    dosing & administration

    TAZVERIK is the only FDA-approved oral monotherapy for R/R FL.1,3

    RECOMMENDED DOSE

    Questions about TAZVERIK?

    Ipsen is here to help. Request to have a representative contact you.

    Ipsen is here to help.
    Request to have a
    representative contact you.

    REQUEST A REP

R/R=relapsed or refractory; EZH2=enhancer of zeste homolog 2; FDA=Food and Drug Administration; NCCN=National Comprehensive Cancer Network.

References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., August 2024. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 13, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. FDA granted accelerated approval to tazemetostat for follicular lymphoma. News release. Food and Drug Administration. June 18, 2020. Accessed February 17, 2025.

Learn more about how TAZVERIK works in FL.

MECHANISM OF ACTION